Novus coverage, page-2

Thanks for sharing viabert, should be some good upside if the CE mark gets up. Interesting that the review considers the market for Oncosil to be much greater than Sirtex's market. Would be interested to know what data is available to back this claim up.

Immediate market would be pancreatic Ca, but primary treatment here is usually surgery esp for pancreatic head tumours. Has the company detailed what proportion of pancreatic Ca cases would be suitable candidates? Liver Ca may also be a success, but surely there would need to be large trials against established therapies before Oncosil could break into this market. Have taken a small holding but would appreciate any info.